SCHEMBL5633144

SCHEMBL5633144

Cc1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)c2ccn(Cc3ccncc3)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.45
EPHB4 P54760 2/20 0.45
TEK Q02763 1/20 0.45
NTRK1 P04629 3/20 0.44
NTRK2 Q16620 3/20 0.44
RET P07949 2/20 0.44
PDGFRB P09619 2/20 0.44
CDK8 P49336 2/20 0.44
NTRK3 Q16288 2/20 0.44
MAPK14 Q16539 2/20 0.44
PDGFRA P16234 1/20 0.44
IDH1 O75874 1/20 0.44
BRAF P15056 6/20 0.43
THRA P10827 2/20 0.42
THRB P10828 2/20 0.42
FLT3 P36888 2/20 0.42
AURKB Q96GD4 2/20 0.42
LTK P29376 1/20 0.42
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5959841 0.89 KDR (0.48) KDREPHB4TEKBRAFTHRA
SCHEMBL5959828 0.86 KDR (0.44) KDREPHB4TEKNTRK1NTRK2
SCHEMBL5612143 0.83 EPHB4 (0.52) KDREPHB4TEKPDGFRBBRAF
SCHEMBL5636147 0.83 KDR (0.51) KDREPHB4CDK8BRAFTHRA
SCHEMBL5592723 0.81 RIPK1 (0.46) KDREPHB4TEKBRAFFLT3
SCHEMBL5586028 0.80 BRAF (0.52) KDREPHB4BRAFCA9FLT1
SCHEMBL5959801 0.78 RAF1 (0.42) KDREPHB4TEKNTRK1BRAF
SCHEMBL5592608 0.78 KDR (0.48) KDREPHB4TEKNTRK1NTRK2
SCHEMBL5592591 0.77 KCNQ3 (0.58) KDREPHB4TEKNTRK1NTRK2
SCHEMBL5592906 0.77 KMT2A (0.50) EPHB4IDH1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP claimed
EP-1858879-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-11-28 EP claimed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US claimed
WO-2006076593-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-07-20 WO claimed
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP disclosed
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP disclosed
EP-2397478-A1 1,3-diaryl substituted ureas as modulators of kinase activity. CGI Pharmaceuticals, Inc. (US) 2011-12-21 EP disclosed
EP-2397478-A1 1,3-diaryl substituted ureas as modulators of kinase activity. CGI Pharmaceuticals, Inc. (US) 2011-12-21 EP disclosed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity UCK2, CHUK, AXL KDR 72/4885EPHB4 3357/4885TEK 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.